(Q34248509)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11347962%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

review article

1 reference

title

New developments in anti-HIV chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11347962%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11347962%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

De Clercq E

series ordinal

1

1 reference

31 July 2017

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11347962%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11347962%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11347962%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11347962%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

3-12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11347962%20AND%20SRC:MED&resulttype=core&format=json

Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Sulfated polysaccharides extracted from sea algae as potential antiviral drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

A general model for the surface glycoproteins of HIV and other retroviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

HIV-1 entry inhibitors in the side pocket

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

ADA, a potential anti-HIV drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Azodicarbonamide inhibits T-cell responses in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3'-azido-2',3'-dideoxythymidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

(-)-6-Chloro-2-[(1-furo[2, 3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Thiazolothiazepine inhibitors of HIV-1 integrase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Inhibition of human immunodeficiency virus type-1 integrase by curcumin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Recent developments in HIV protease inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

A Convergent, Scalable Synthesis of HIV Protease Inhibitor PNU-140690

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

7 January 2021

Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

7 January 2021

Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

7 January 2021

Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

7 January 2021

Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

7 January 2021

Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901007-2

7 January 2021

10.1016/S0014-827X(01)01007-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11347962%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference